


INFORMATION DISCLOSURE CITATION



Docket No.: RLL 03US

Serial No.: 09/998,115

Applicants: Anand, *et al.*

Filed: 11/30/2001

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FB	A1	4,479,954	10/30/1984	Hirose <i>et al.</i>	424	251	RECEIVED MAY 24 2002 TECH CENTER 1600/2900
FB	A2	4,524,206	6/18/1985	New <i>et al.</i>	544	230	
FB	A3	4,598,078	7/1/1986	Ishizumi <i>et al.</i>	544	252	
FB	A4	6,083,950	7/4/2000	Anand, <i>et al.</i>	544	252	
FB	A5	6,090,809	7/18/2000	Anand, <i>et al.</i>	544	252	
FB							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
FB	B1	WO 98/37893	9/3/1998	PCT				X
FB	B2	WO 98/51298	11/19/1998	PCT				X
FB	B3	JP 59036661	2/28/1984	Japan			X Abstract only	
FB	B4	JP 60-204784	10/16/1985	Japan			X Abstract	
FB	B5	JP 02-235865	9/18/1990	Japan			X Abstract	
FB	B6	EP 0 109 562 A1	5/30/1984	EPO				
FB	B7	EP 0 111 226 A1	6/20/1984	EPO				
FB	B8	EP 0 711 757 A1	5/15/1996	EPO				
FB	B9	AT 387 773 B	3/10/1989	Austria				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

FB	C1	HIEBLE <i>et al.</i> , "Recent advances in the identification of alpha1- and alpha2-adrenoceptor subtypes: therapeutic implications", <u>Expert Opinion on Investigational Drugs</u> 6, pp. 367-387 (1997)
FB	C2	KENNY <i>et al.</i> , "Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia", <u>J. Med. Chem.</u> 40, pp.1293-1315 (1997)


EXAMINER

FB Benkard

DATE CONSIDERED

7/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION 	Docket No.: RLI 03US	Serial No.: 09/998,115
	Applicants: Anand, <i>et al.</i>	
	Filed: 11/30/2001	Group: TECH CENTER 1600/2900

FB	C3	CROSS, <i>et al.</i> , "Substituted trifluoromethyl phenyl piperazines as anorectic agents", <u>Eur. J. Med. Chem. - Chimica Therapeutica</u> <u>12</u> , pp 173-176 (1977)
FB	C4	VAN STEEN, <i>et al.</i> , "A Series of N4-Imidoethyl Derivatives of 1-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazine as 5-HT _{1A} Receptor Ligands: Synthesis and Structure-Affinity Relationships", <u>J. Med. Chem.</u> <u>38</u> , pp. 4303-4308 (1995)
FB	C5	ISHIZUMI, <i>et al.</i> , "Synthesis and Anxiolytic Activity of N-Substituted Cyclic Imides (1 <i>R</i> *,2 <i>S</i> *, 3 <i>R</i> *, 4 <i>S</i> *)-N-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-2,3-bicyclo[2.2.1]heptanedicarboximide (Tandospirone) and Related Compounds ^{1,2} ", <u>Chem. Pharm. Bull.</u> <u>39</u> (9), pp. 2288-2300 (1991)
FB	C6	NEW, <i>et al.</i> , "Buspirone Analogues. 2. Structure-Activity Relationships of Aromatic Imide Derivatives", <u>J. Med. Chem.</u> <u>29</u> , pp. 1476-1482 (1986)
FB	C7	KORGAONKAR, <i>et al.</i> , "Synthesis of N-[3-(4-Aryl-1-piperazinyl)propyl]-4, 4-bis(4-methoxyphenyl)piperidine-2,6-diones/Tetrahydrophthalimides/Camphorimides as Sedatives", <u>J. Indian Chem. Soc. Vol. LX</u> , pp. 874-876 (1983)
FB	C8	KHADILKAR & SAMANT, "Synthesis and Pharmacology of Some 2-[3-(4-Aryl-1-piperazinyl)propyl]-1 <i>H</i> -benz[<i>de</i>]isoquinolin-1,3(2 <i>H</i>)-diones/2,5-pyrrolinediones", <u>J. Indian Chem. Soc.: Vol. LXIII</u> , pp. 529-530 (1986)
FB	C9	SAMANT & KULKARNI, "N-(N ⁴ -Aryl-N ¹ piperazinylmethyl)-4-(4-methoxyphenyl)-piperidine-2,6-diones : CNS Depressants", <u>J. Indian Chem. Soc. Vol. LV</u> , pp. 819-821 (1978)
FB	C10	SAMANT & KULKARNI, "Synthesis and Pharmacology of N-(N ⁴ -Aryl-N ¹ -Piperazinylalkyl) Phthalimides : CNS Depressants", <u>J. Indian Chem. Soc. Vol. LVI</u> , pp. 1002-1005 (1979)
FB	C11	Michel, <i>et al.</i> , "Identification of a single α_1 -adrenoceptor corresponding to the α_{1A} -subtype in rat submaxillary gland", <u>Br. J. Pharmacol.</u> <u>98</u> , pp 883-889 (1989)
FB	C12	U'PRICHARD, <i>et al.</i> , "Prazosin: Differential Affinities for Two Populations of α -Noradrenergic Receptor Binding Sites", <u>Eur. J. of Pharm.</u> <u>50</u> , pp.87-89 (1978)
	C13	CHENG & PRUSOFF, "Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition(I₅₀) of an enzymatic reaction", <u>Biochem Pharmacol</u> <u>22:23</u>, pp. 3099-108 (1973)

EXAMINER	<i>F Benbraud</i>	DATE CONSIDERED	<i>7/26/02</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION

Docket No.: RLI 93US

Serial No.: 09/98 115

Applicants: Anand, et al.

Filed: 11/30/2001

Group:



RECEIVED
MAY 24 2002
TECH CENTER 1600/2900

FB	C14	BRUNE, et al., "Effects of Selective and Nonselective Alpha-1-Adrenoceptor Antagonists on Intraurethral and Arterial Pressures in Intact Conscious Dogs", <u>Pharmacology</u> 53, pp. 356-368 (1996)
FB	C15	ZAGIDULLIN, "N-(.beta.-Aminoethyl)piperazine-and-its-derivatives-in-aminomethylation reactions", <u>Zh. Obshch. Khim.</u> , vol. 16, no. 1, pp. 247-253 (1991)
	C16	ZAGIDULLIN, "N-(.beta.-Ethylaminopiperazine) and its derivatives in a Mannich Reaction", <u>Khim. Yvsokomol. Soedin. Neftekhim.</u>, pp. 44-45 (1973)

EXAMINER

F Bernhard

DATE CONSIDERED

7/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.